No headlines found.
Business Wire (Wed, 11-Dec 8:03 AM ET)
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Business Wire (Tue, 12-Nov 4:10 PM ET)
Globe Newswire (Tue, 5-Nov 4:00 PM ET)
Business Wire (Mon, 4-Nov 4:00 PM ET)
Alto Neuroscience to Participate in Upcoming Investor Conferences
Business Wire (Mon, 4-Nov 8:00 AM ET)
Business Wire (Tue, 22-Oct 9:53 PM ET)
Business Wire (Tue, 22-Oct 4:30 PM ET)
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.
As of January 15, 2025, ANRO stock price climbed to $4.49 with 54,618 million shares trading.
ANRO has a beta of 2.86, meaning it tends to be more sensitive to market movements. ANRO has a correlation of 0.06 to the broad based SPY ETF.
ANRO has a market cap of $121.05 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
ANRO support price is $4.22 and resistance is $4.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.